News | May 21, 2018

Intramural Needle Ablation Effective for Refractory Ventricular Arrhythmias

Intramural Needle Ablation Effective for Refractory Ventricular Arrhythmias. #HRS2018

May 21, 2018 — The available electrophysiology catheter ablation technologies are not designed for use in the ventricular anatomy, so a new needle ablation catheter from Biosense Webster was tested in a study to assessed the safety.[1] The six-month data from the study was presented at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions.

All of the patients had failed using a standard approach and then using the needle we were able to get rid of their tachycardia

All 31 patients included in the trial failed standard ablation and medical therapy. However, the needle-based system was able to eliminate their tachycardia. 

Intramural origin is an important cause of ventricular arrhythmia (VA) ablation failure that we are attempting to address with an irrigated needle ablation catheter. This study assessed the safety and six-month outcome of irrigated needle ablation in patients with sustained monomorphic ventricular tachycardia (VT) and structural heart disease or nonsustained ventricular arrhythmia and left ventricular (LV) dysfunction not responsive to antiarrhythmic drugs and standard catheter ablation. 

Patients were enrolled at three centers. At putative target sites selected based on endocardial mapping, the 27 gauge needle was deployed up to 10 mm into the myocardium for recording and pace mapping. Then irrigated with contrast/saline for radiofrequency (RF) ablation with current titrated to a maximum needle temperature of 60 degrees Centigrade.

Irrigated needle ablation was performed in 31 patients at the three centers. Most patients had nonischemic heart disease (NICM) with sustained monomorphic VT (table). A median of 15 RF needle applications per patient were delivered to selected RV/LV septum and free wall sites.


Links to all the Heart Rhythm 2018 Late-breaking Studies



1. Intramural Needle Ablation for the Treatment of Refractory Ventricular Arrhythmias. Identifier: NCT03204981.


#HRS2018 #HRS18

Related Content

Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
Overlay Init